Osel Sees Immunotherapy-Like Trajectory For Oncology Microbiome Candidate

 
• By Alaric DeArment

Depending on financing, the company could start a Phase III trial of CBM588 as early as this year, but it’s looking to develop the microbiome therapeutic for a potentially broad array of cancers.

Bacterias 3D rendering
Osel announced results of a Phase I trial combining its microbiome therapy with BMS's Opdivo • Source: Shutterstock

More from Anticancer

More from Therapy Areas